Efficacy and Safety Analysis of Risperidone and rTMS Drugs in the Treatment of Alzheimer's Disease with Psychobehavioral Symptoms

To investigate the effectiveness and safety of risperidone and rTMS for Alzheimer's disease (AD) with behavioral and psychological symptoms of dementia (BPSD). 100 patients with AD and BPSD from March 2019 to June 2021 divided into control group and observation group in which 50 cases respectively. The control group received risperidone, and the observation group was given risperidone combined with rTMS. Both groups were treated for 12 weeks. Then Psychiatric Questionnaire (NPI), Brief Psychiatric Assessment Scale (BPRS) and Simple Mental State Examination Scale (MMSE) scores, Alzheimer's Disease Cognitive Function Assessment Scale (ADAS-C A g) and Activities of daily living (ADL) scores and adverse reactions were measured. The observed group were more efficient than that of the control group (p < 0.05). The NPI and BPRS scores were lower than before treatment and the MMSE score was higher than before treatment (p < 0.05); the observation group had lower NPI and BPRS scores t and higher MMSE score than control group (p < 0.05),In both groups, patients had lower ADAS-Cog scores for 12 weeks than before treatment and higher ADL scores than before treatment (p 0.05); and lower ADAS-Cog scores and higher ADL scores than control group (p < 0.05).There was no significant difference in adverse effects between 2 groups (p > 0.05). risperidone combined with rTMS treatment can effectively improve the mental and behavioral symptoms of AD patients, with high safety, is more significant, can avoid the possible adverse reactions caused by drug dosage, and has the value of clinical promotion and application.